OCGN
Ocugen, Inc.
NASDAQ · Healthcare · Biotechnology · US
$0.86
+16.00%Next report
Analyst consensus
- Next report date
- Nov 4, 2026
- EPS estimate
- -$0.06
- Revenue estimate
- $1.3M
Latest reported
- Last report date
- Nov 4, 2026
- EPS actual
- -$0.06
- EPS estimate
- -$0.06
- Revenue actual
- $2.0M
- Revenue estimate
- $1.3M
Track record
Trailing twelve quarters
- EPS beats (12Q)
- 5
- EPS misses (12Q)
- 3
- EPS in line (12Q)
- 4
- Avg surprise (4Q)
- -12.8%
- Revenue beats (12Q)
- 7
Reported history
| Report date | EPS estimate | EPS actual | Surprise | Revenue actual |
|---|---|---|---|---|
| Nov 4, 2026 | -$0.06 | -$0.06 | In line | $2.0M |
| Aug 6, 2026 | -$0.05 | -$0.07 | Miss -31.26% | $1.5M |
| May 5, 2026 | -$0.05 | -$0.06 | Miss -20.00% | $1.5M |
| Mar 4, 2026 | -$0.06 | -$0.06 | In line | -$193.0K |
| Nov 5, 2025 | -$0.06 | -$0.07 | Miss -21.74% | $1.8M |
| Aug 1, 2025 | -$0.06 | -$0.05 | Beat 16.67% | $1.4M |
| May 9, 2025 | -$0.06 | -$0.05 | Beat 16.67% | $1.5M |
| Mar 5, 2025 | -$0.05 | -$0.05 | In line | $764.0K |
| Nov 14, 2024 | -$0.05 | -$0.05 | In line | $1.1M |
| Aug 8, 2024 | -$0.06 | -$0.04 | Beat 33.33% | $1.1M |
| Apr 16, 2024 | -$0.06 | -$0.04 | Beat 33.33% | $1.0M |
| Nov 9, 2023 | -$0.08 | -$0.06 | Beat 25.00% | — |
Reported results against consensus at the time of each report · Surprise is computed from the estimate on record · Data as of Mar 3, 2027